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INTRODUCTION
`Human materials' are increasingly being used in developing medical
products under the impetus of the life sciences. Many of these new products
are seen as part of the global trend toward `regenerative medicine', a new
paradigm for medicine itself. Such developments attract the attention of law
making and regulation, with the goals of protecting and improving public
health, ensuring safety, and advancing scientific and industrial ambitions.
These developments are producing significant shifts in the relationships
between the human and material worlds, bringing them closer together and
complicating their distinction. Such shifts have been theorized by sociologists
using terms such as `biomedicalization'.1 Human tissues, cells, and genes
have become the object of regulation worldwide, including new laws in the
European Union, which has caused `a major reshaping of the regulatory
landscape of the life-sciences in Member States'.2 As will be seen in this
discussion, the new EU law raises a number of issues that are important to
analysis from the perspectives of socio-legal studies and science and
technology studies. Conspicuous amongst these is the issue of how legal
concepts and regulatory institutions can be `matched' to the scientific,
technological, and industrial categories that emerge in the development and
testing of complex new medical materials, and how these vary in the framings
of different, bounded legal regimes such as national political cultures, build-
ing on existing regimes.3 Scientists and governments are faced with products
derived from living matter, which are, by definition, much more difficult to
stabilize than manufactured products using and processing inert materials.
As will be shown below, a new EU `advanced therapy' regulation defines,
more or less, what henceforth does and does not constitute a human
materials-derived medical product `within the law', and it also leaves open
some key questions about how certain classes of medical artefact, produced
under certain circumstances, might be regulated when they fall outside the
EU-wide regime that the new regulation established. Crucially, for example,
this raises issues of what types of social actors in what types of institutions
may participate in the EU regime of regenerative medicine,4 either as
1 A.E. Clarke et al., `Biomedicalization: Technoscientific transformations of health,
illness, and US biomedicine' (2003) 68 Am. Sociological Rev. 161±94.
2 M. Favale and A. Plomer, `Fundamental disjunctions in the EU legal order on human
tissue, cells and advanced regenerative therapies' (2009) 16Maastricht J. of European
and Comparative Law 89±111.
3 V. Tournay (ed.), La gouvernance des innovations meÂdicales (2007).
4 We use the term `regenerative medicine' to refer broadly to the field under discussion
even though it is not equivalent to `advanced therapy medicinal products'. We do so
because it has become a widely used term, especially amongst participating scientists
and industry, and is also known to the public, rather than because it has a legal
definition. As used here, it may refer to a range of therapeutic applications such as
prevention and repair as well as strictly `regeneration'.
producers or users/consumers. The discussion below will show how the new
legal regimes grapple with trying to define delicate distinctions between, for
example, what is and is not a `hospital', what is and is not an `industrial
process' using human materials, and how the borderline is drawn between
commodification and non-commodification or commercialization.5 The new
regulation thus enters into the heart of the professional working routines and
standards involved in the biotherapeutic manufacturing process. In order to
highlight these questions, therefore, we focus in particular in this discussion
on the borderline between what is and what is not included in the new EU
human tissues and cells and advanced therapy regimes, on some of the most
relevant rules regarding clinical trials for new medical entities, and how
these matters are being approached institutionally and in terms of the legal
conceptualization of human materials, in two contrasting EU countries,
namely, France and the United Kingdom.
Perhaps the most conspicuous feature of the legal landscape for the
scientific research, materials, and products of regenerative medicine, is its
sheer complexity. Much of this complexity is illustrated in the descriptions
of relevant laws provided in the body of this paper. To some extent this
complexity is ironic, given the aim of the European Commission to provide
`legal clarity' and harmonization within the European area through the
development of a new legal regime. The question of the extent to which this
complexity and instability is, as it were, the `natural' reflection of the
biologies and ever-evolving living technologies involved, or the extent to
which it is more the result of interacting regulatory, social and ethical, and
institutional forces, is a key one that the article addresses. Regardless, dif-
ferent countries are tackling the regulation of these materials and associated
sciences and technologies in widely different ways, resulting in a segmented
marketplace of different regulatory regimes involved in constituting the
emerging worlds of the new regenerative medicine paradigm.
The article now turns to consider the recent developments in EU law
relating to regenerative medicine in the form of its `starting materials' of
tissues and cells, and the new category of `advanced therapy' which is the
outcome of several years' protracted negotiation between stakeholders in this
field.
5 In this paper, we consider that the English `non-commodification' corresponds to the
French principle of `non-patrimonialiteÂ' of the human body and its elements, which
means that the human body and its elements cannot be the object of a financial
agreement.
REGENERATIVE TECHNOLOGIES AND MEDICAL MATERIALS
REGULATED BY EU LAW: LEGAL REGIMES ENFORCEABLE IN
FRANCE AND THE UNITED KINGDOM
Human cells and tissues have been identified as a distinct category of
medical material for legislation in the EU, and an entirely new category of
product has also been devised by regulators, namely, `Advanced Therapy
Medicinal Products' (ATMP). This `advanced therapy' designation does not
exist as a legal categorization elsewhere in the world. Advanced Therapy
Medicinal Products have been defined in the EU as medicinal products based
on genes, cells or tissues. Gene therapy,6 for example, targeted at cancer
cells or aimed to replace defective genes in diseases with genetic causation
such as cystic fibrosis, and cell therapy,7 for example, a patient's cartilage
cells extracted, multiplied, and re-implanted, have been regulated as
medicinal products under the EU general legal framework since 2003.8
But tissue-engineered products9 (TEPs), for example, `living skin' including
a layer of manufactured biomaterial, lay outside any EU legislation.
In Europe, products utilizing human tissues/cells may be regulated either
by EU law or by national laws, depending on the determined material and
legal character of the `product' and/or the institutional and work-routine
features of the process of preparing it. A comparative approach can shed
6 Gene therapy medicinal products means:
a biological medicinal product which has the following characteristics: it contains
an active substance which contains or consists of a recombinant nucleic acid used
in or administered to human beings with a view of regulating, repairing, replacing
adding or deleting a genetic sequence; its therapeutic, prophylactic or diagnostic
effect relates directly to the recombinant nucleic acid sequence it contains, or the
product of genetic expression of this sequence. Gene therapy medicinal products
shall not include vaccines against infectious diseases.
Annex, Part IV, 2.1 of Directive 2009/120/EC.
7 A somatic cell therapy medicinal product means a biological medicinal product
which:
contains or consists of cells or tissues that have been subject to substantial
manipulation so that biological characteristics, physiological functions or
structural properties relevant for the intended clinical use have been altered, or
of cells or tissues that are not intended to be used for the same essential func-
tion(s) in the recipient and the donor; [and] is presented as having properties for,
or is used in or administered to human beings with a view to treating, preventing
or diagnosing a disease through the pharmacological, immunological or metabolic
action of its cells or tissues.
Annex, Part IV, 2.2 of Directive 2009/120/EC.
8 Directive 2003/63/EC of 25 June 2003, amending Directive 2001/83/EC of the
European Parliament and of the Council on the Community code relating to medicinal
products for human use, OJ L159/46, 27.06.2003.
9 A tissue engineered product contains or consists of engineered cells or tissues (of
human or animal origin or both, viable or non-viable), and is presented as having
properties for human beings to regenerate, repair or replace a human tissue:
Regulation (EC) No. 1394/2007 on ATMP, Article 2.1(b).
light on the complexity and flexibility of different national regimes within
the over-arching EU risk-based regime.10 Thus, we will analyse and compare
how France and the United Kingdom, both countries with relatively high
levels of activity in the regenerative medicine sector, regulate medical
materials and advanced therapy medicinal products which do and do not fall
under the scope of the new EU laws applicable to regenerative products
using human materials.
The structure of the discussion is as follows. First, we explain the legal
frame for tissues and cells used in therapy and manufactured as products
regulated by EU law, as it is enforceable in every EU member state, noting
differences in implementation between France and the United Kingdom.
Secondly, analysis will be presented of how each country regulates products
which remain not covered by EU law. This raises the issue of the `industrial
process' of routine production of therapies, by which the new regulation
attempts to distinguish commercial enterprise from `hospital'-based prepara-
tion of therapies for single patients on a one-off basis, a key point of
negotiation and conflict during the political discussion of the new products
Regulation.
THE LEGAL FRAME FOR TISSUES AND CELLS USED FOR
HUMAN APPLICATIONS AND PREPARED OR
MANUFACTURED FOR USE IN OR AS PRODUCTS
Three main fields particularly relevant for companies and other establish-
ments developing regenerative medicine products using tissues and cells
have been regulated at EU level: (i) the use of human tissues and cells for
human application; (ii) clinical trials; and (iii) marketing authorization and
follow-up of regenerative/advanced therapy medicinal products (ATMPs).
Below we describe each of these in turn. These sets of laws and regulations
are highly complex, and we therefore of necessity summarize the main legal
measures and institutional aspects as they refer to the biological materials
and products.
1. The EU regulation of tissues and cells as medical materials
Tissues and cells, when considered as medical materials, have to rely on two
pieces of legislation divided according to the chain from procurement to the
distribution of the final medicinal products. On the one hand, three EU
Directives have been developed to regulate the procurement and use of
human tissues and cells for human application. Directive 2004/23/EC of
10 See A.-M. Farrell, `The politics of risk and EU governance of human material' (2009)
16 Maastricht J. of European and Comparative Law 41±64.
31 March 2004, often called the `` mother directive'' (also known in short-
hand as the `Tissues and Cells' Directive, or sometimes, and more infor-
matively, the `tissue banking' Directive), provides the framework
legislation,11 and two supplementary technical Directives provide detailed
requirements.12 These Directives establish quality and safety standards. On
the other hand, where a product enters in the scope of the Regulation on
ATMP,13 the Tissues and Cells Directive will only apply for the donation,
procurement, and testing phases of the medical materials. The later steps
(processing, storage, and distribution) have to comply with the Regulation on
ATMP14 which concerns medicinal products (see below). This means that
two complementary sets of rules have to be respected. Interestingly, one
main institution, AFSSAPS-French Agency for the Safety of Health
Products, will control the enforcement of these rules in France although an
opinion may be required from the Biomedecine Agency,15 whereas, in the
United Kingdom, at least three agencies are in place to cover the whole chain
of human materials activity: the Human Tissue Authority (HTA) for the
regulation of tissues and cells other than gametes and embryos for human
application, the Human Fertilisation and Embryology Authority (HFEA)16
for the regulation of gametes and embryos for human application, and the
Medicinal and Healthcare products Regulatory Authority (MHRA) for
medicinal products based on human body elements.
The directives on tissues and cells have been transposed into British17 and
French18 laws. In France, AFSSAPS19 is in charge of the technical imple-
11 Directive 2004/23/EC of the European Parliament and of the Council of 31 March
2004 on setting standards of quality and safety for the donation, procurement, testing,
processing, preservation, storage and distribution of human tissues and cells, OJ
L102/48, 07.04.2004.
12 Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC as
regards certain technical requirements for the donation, procurement and testing of
human tissues and cells, OJ L38/40, 09.02.2006, and Directive 2006/86/EC of 24
October 2006, implementing Directive 2004/23/EC as regards traceability require-
ments, notification of serious adverse reactions and events, and certain technical
requirements for the coding, processing, preservation, storage, and distribution of
human tissues and cells, OJ L294/32, 25.10.2006.
13 ATMP Regulation, op. cit., n. 9, Preamble (6).
14 id., Article 3.
15 The French Biomedecine Agency was set up by the 2004 Bioethics Law. It is the
reference authority for medical, scientific, and ethical aspects, notably those related to
procurement and transplant of organs, tissues, and cells: <http://www.agence-
biomedecine.fr/>.
16 HFEA, at <http://www.hfea.gov.uk/>.
17 Human Tissue (Quality and Safety for Human Application) Regulations 2007: these
Regulations complete the Human Tissue Act 2004 which covers England, Wales, and
Northern Ireland (Scotland has separate provision).
18 In France, many legal texts implement those directives: notably, Law n2011-814 of 7
July 2011 on bioethics, French OJ n157, 08.07.2011, 11826, text n1.
19 AFSSAPS, at <http://www.afssaps.fr/>.
mentation of the regulation. French law does not only provide stringent
safety requirements for human tissues and cells, it also protects them through
fundamental rights and, notably, the principle of respect for human dignity as
elements of the human body through the integration of measures protective
of the human body within the civil code regarding the respect due to the
person.
In the United Kingdom, the HTA20 detailed in specific guidance the
standards required under the Human Tissue Regulations.21 The over-
whelming weight of provision in the United Kingdom's Human Tissue Act is
devoted to elucidating the principles of informed consent by patients.
However, the abolition of the HTA and the HFEA is being discussed in
the United Kingdom (spring 2011). A previous review in December 2006
proposed to merge the HTA and the HFEA into a single Regulatory
Authority for Tissue and Embryos22 and the positioning of these bodies is
again the subject of government attention. This question was debated on 1
February 2011 where a spokesman for the Department of Health stated that
his department was `planning to undertake a public consultation exercise . . .
about where HFEA and HTA functions are best transferred'.23 Nevertheless,
the existence of two agencies presents the advantage of distinguishing
clearly the two sets of rules enforceable for human tissues and cells either as
raw materials or as medicinal products once transformed by a biomanufac-
turing process. But, at the same time, it could be seen as a more complex
framework for researchers and manufacturers who might have difficulties
understanding the remit of each agency. Equally, in France, it may be
considered inconsistent, ambiguous, and potentially a conflict of interest to
highlight the significance of the implementation of fundamental rights to
human body elements while the same agency also controls both the procure-
ment of human body elements and the development of health products based
on them. However, the Biomedecine Agency appears to have a safeguard for
ethical matters, in particular through its advisory council, even though this is
not an ethics committee. Thus, we can see that, whereas the weight of the
implementation of the law in France is on non-commodification, in the
United Kingdom the major focus is more on the institutionalization of
individual consent procedures for allowing but controlling citizens' and
patients' rights over use of body materials.
20 HTA, at <http://www.hta.gov.uk/>.
21 HTA, Guide to Quality and Safety Assurance of Human Tissues and Cells for Patients
Treatments (2010); HTA Directions 003/2010 relating to licences granted under the
Human Tissue (Quality and Safety for Human Application) Regulations 2007.
22 Department of Health, Review of the Human Fertilisation and Embryology Act:
Proposals for revised legislation (including establishment of the Regulatory Authority
for Tissue and Embryos) (2006; Cm. 6989).
23 Earl Howe, 724 H.L. Debs col. GC 343 (1 February 2011).
2. EU regulation of clinical trials
Regenerative or advanced therapy products have been deemed to be high-
risk products which will therefore require clinical trials to place them in the
European marketplace. Directive 2001/20/EC on clinical trials for medicinal
products for human use24 and Directive 2005/28/EC for good clinical
practice25 as regards investigational medicinal products,26 and authorization
of their manufacture or importation, apply to regenerative medicine
products. The Regulation on ATMP, detailed below, extended application
of the therapy-specific rules to tissue-engineered products27 and to the
adoption of guidelines specific to ATMPs.28
Two main specific rules apply to clinical trials involving an advanced
therapy product. First, the usual 60-day decision period following a valid
clinical trial application can been extended to 90 days for products based on
human body elements, and it may be doubled where the consultation of a
group or a committee is deemed required by the member state concerned.29
Secondly, while the non-opposition of the authority is usually sufficient to
start a clinical trial, an explicit written authorization is required for trials
involving ATMPs or any medicinal product containing genetically modified
organisms, indicating the high degree of risk perceived.30 Apart from EU
clinical trials law, France and the United Kingdom each have specific
measures regarding the clinical trials of products based on human body
elements, which we note below.
In France, EU law on clinical trials applies to medicinal products derived
from gene therapy 31 and from cell therapy which are still considered to be
medicinal products in French law. Thus it applies to gene therapy, that is,
pharmaceutical products and preparations32 derived from gene therapy, and
24 OJ L121/34, 01.05.2001.
25 OJ L91/13, 09.04.2005.
26 Directive 2001/20/EC, Article 2(d), defines an `investigational medicinal product'
as:
a pharmaceutical form of an active substance or placebo being tested or used as a
reference in a clinical trial, including products already with a marketing
authorization but used or assembled (formulated or packaged) in a way different
from the authorized form, or when used for an unauthorized indication, or when
used to gain further information about the authorized form.
27 ATMP Regulation, op. cit., n. 9, Article 4(1).
28 European Commission, Detailed guidelines on good clinical practice specific to
advanced therapy medicinal products, 3 December 2009, ENTR/F/2/SF/dn D(2009)
35810.
29 Directive, op. cit., n. 26, Articles 6(7) and 9(4).
30 id., Article 9(6).
31 Article L5121-8 of the French Public Health Code. They are prepared in advance and
according to an industrial process. Thus, they are submitted to EU legislation on
ATMP and to a centralized marketing authorization.
32 Article L5121-1-12ë of the French Public Health Code. They are prepared in advance
and to one or several patients on medical prescription. As there is no industrial
to cell therapy,33 that is, pharmaceutical products derived from human and
xenogeneic (animal materials-based) cell therapy34 and preparations derived
from xenogeneic cell therapy.35 When the research involves genetically
modified organisms, the highest possible level of authorization is invoked, so
the clinical trial application dossier must comprise the classification of the
organism by the Haut Conseil des Biotechnologies (High Council of Bio-
technologies ± HCB)36 and the consent of the Ministry in charge of
research.37 However, importantly, preparations derived from human cell
therapy are never considered as medicinal products in French law.
Consequently, they fall under the legal regulations governing human cells
and tissues38 discussed above, including for clinical trials,39 as distinct from
the ATMP product Regulation discussed below. The regime for tissue
engineering is identical as for cell therapy.
In the United Kingdom, a specific national `Gene Therapy Advisory
Committee' (GTAC) has responsibility for the ethical review of research
study involving not only gene therapy, but also embryonic stem-cell therapy,
cell therapies derived from stem-cell lines, and the therapeutic use of
genetically modified stem cells or therapeutic xenotransplanation.
Interestingly, from 1 May 2008, the GTAC can transfer applications to
other (locally-based) Research Ethics Committees if a gene therapy proposal
is deemed to be `low genetic risk'.40 The notion of `low genetic risk' can be
regarded as a technical tool, set up by the GTAC itself. In spite of a `decision
tree'41 indicating the regulatory routing of products, this notion is not clearly
defined. In France, such a concept does not exist, but neither is the range of
applications covered by the HCB clearly defined. Although the HCB to date
has given opinions on gene therapy only, its mission also covers `other
biotechnologies'.42 Thus, in legal terms, it seems there is a non-defined
process, they are not submitted to the EU legislation on ATMP. The marketing
authorization is delivered by AFSSAPS for a specific therapeutic use.
33 Article L1243-1 of the French Public Health Code.
34 Art. L5121-8, op. cit., n. 31.
35 Article L5121-1-13ë of the French Public Health Code.
36 The HCB replaces the Commission de GeÂnie GeÂneÂtique (Genetic Engineering
Committee) and the Commission d'eÂtude de la disseÂmination des produits issus de
geÂnie biomoleÂculaire (Committee for studying the dissemination of products derived
from biomolecular engineering).
37 See, notably, Articles R1125-1, R1125-3, R1125-8, R1125-10, and R1125-11 of the
French Public Health Code.
38 Article L1243-1 of the French Public Health Code.
39 Article R1243-1 of the French Public Health Code, and Decree 2008-968 (DeÂcret no
2008-968 du 16 septembre 2008 (autorisations d'activiteÂs et de produits)).
40 Amendment of regulation 15 of the Clinical Trials Regulations, 3(c)(4B) of the
Medicines for Human Use (Clinical Trials) and Blood Safety and Quality
(Amendment) Regulations 2008 S.I. 2008/941.
41 Department of Health, GTAC, Agreed Decision tree, at: <http://www.dh.gov.uk/prod_
consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_087984.pdf>.
42 Article L531-3 of the French Environment Code.
stratification of risks for clinical trials of such health products, associated
with institutional flexibility. In both cases, it appears therefore that there is
significant scope for discretionary decision making, under conditions of
uncertainty, on a case-by-case basis by constituted groups of experts, in spite
of, or at least alongside, the complex decision trees and specific national-
level regulatory institutions that have been developed.
It is interesting to note that in both France and the United Kingdom, there
is a specific committee in charge of the assessment of risks for particular
gene therapy. The remit regarding the range of types of product of the HCB
in France is wider than that of the GTAC in the United Kingdom, showing
that there can be flexibility built in to the scope of apparently specifically-
designed regulatory bodies, partly for the pragmatic reason of the limited
available expertise and its organization, and pointing to the unstable and
open-ended nature of the regulated objects.
3. The EU regulation for marketing authorization and follow-up of
regenerative products as advanced therapy medicinal products
Commercial establishments brought under regulation of EU competition laws
are brought into an EU `harmonized' regime. On 13 November 2007, the EU
adopted a lex specialis43 addressing what were then legally termed advanced
therapies, including TEPs, within a claimed single coherent framework in
order to bridge the pre-existing regulatory gap for TEPs: Regulation (EC) No.
1394/2007 (`the Regulation on ATMP').44 This includes a provision for a
central and unique marketing authorization at the European Medicines
Agency (EMA) level where a new Committee for Advanced Therapy (CAT)
has been created,45 meaning that once authorized, products may be made
available throughout the EU member states without recourse to separate
national marketing authorizations.
Since the adoption of the Regulation on ATMP, four types of biological
medicinal products based on genes, cells, and tissues are regulated at EU
level: gene therapy medicinal products (GTMP), somatic cell therapy
medicinal products (CTMP), tissue-engineered products (TEPs), and com-
bined ATMP46 which associates a medical device with an advanced therapy.
The EMA can provide an informal scientific recommendation on the
43 The Latin `lex specialis' notion comes from the legal maxim `lex specialis derogat
legi generali'. A `lex specialis' is a `law' which governs a specific subject matter. The
legal maxim means that a law governing a specific subject matter overrides a law that
only governs general matters. For our subject, Regulation (EC) No. 1394/2007
overrides the general EU pharmaceutical legislation.
44 OJ L324/121, 10.12.2007.
45 The Marketing Authorization is granted by the European Commission after
consulting the new CAT and the Committee for Medicinal Products for Human
Use within the EMA.
46 ATMP Regulation, op. cit., n. 9, Article 2.1(d).
classification of products.47 The Regulation applies to products which
correspond to the EU legal definitions and `which are intended to be placed
on the market in Member States and are either prepared industrially or
manufactured by a method involving an industrial process'48 (our emphasis).
Unsurprisingly perhaps, there are difficulties in distinguishing which
products are covered and which are not. The European Commission has
tried to clarify the `industrial process':
This should cover, inter alia: Any `mass production' of advanced therapy
products for allogeneic use (batch production, `off the shelf' products etc.);
any advanced therapy product for autologous use (i.e. using cells/tissues from
a single patient and re-implanting after manipulation into same patient) which,
although being patient-specific by definition, is manufactured in accordance
with a standardised and industrial process.49
This classificatory distinction is crucial to defining the status and respon-
sibilities of producers of regenerative products, whether in hospitals or in the
commercial sector, and was the subject of major debate amongst interested
stakeholders in the negotiation of the Regulation.50 The Regulation also
strengthens `post-authorization' requirements51 and provides a reinforced
traceability.52
The ATMP Regulation is directly enforceable in British and French laws,
which have been modified to comply with EU law through the Medicines for
Human Use (Advanced Therapy Medicinal Products and Miscellaneous
Amendments) Regulations 2010 for the United Kingdom, and a new law
adapting French law to the EU law adopted on 22 March 201153 in which
Article 8 is devoted to ATMP for France.
Having described and discussed the regulation of human tissues and cells
as medical materials, clinical trial aspects, and products as advanced
therapies, we turn, secondly, to examine the question of body elements and
products which may remain not covered by these EU-level laws. As noted in
our introduction, this highlights further the question of under what
circumstances is a product to be regarded as prepared by an `industrial
process,' which has direct consequences for the regimes that will apply and
the commercial and safety interests of producers and consumers ± companies,
hospitals, physicians, and patients.
47 id., Article 17.
48 id., Preamble (6).
49 Commission staff working document.
50 See A. Faulkner, Medical Technology into Healthcare and Society (2009) ch. 8.
51 ATMP Regulation, op. cit., n. 9, Article 14.
52 id., Article 15.
53 Law 2011-302 of 22 March 2011, J. Officiel De La ReÂpublique FrancËaise (23 mars
2011) texte no 6.
REGENERATIVE TECHNOLOGIES NOT REGULATED BY EU LAW
AS ADVANCED THERAPY MEDICINAL PRODUCTS: THE
INFLUENCE OF EU LAW IN FRANCE AND THE UNITED KINGDOM
1. Tissues and cells for graft or transplant
In France and the United Kingdom, tissues and cells used for graft or
transplant are not classified as medicinal products. They are regulated in
order to comply with the EU Directives on tissues and cells outlined above.
In France, the regulation of human tissues and cells for therapeutic
purposes is the same as for `preparations' of human cell therapy. Producers
must obtain an authorization from AFSSAPS, after assessment of their
processes for preparation and preservation, as well as their therapeutic
indications, and after advice and consent from the Biomedecine Agency.54
Various specific decrees have been drawn up such as Decree no. 2008-96855
which makes a distinction between institution authorization for preparation,
preservation, distribution and transfer of tissues, their by-products, cells and
preparations derived from cell therapy and authorization of the processes for
such materials.56
In the United Kingdom, on the other hand, an establishment which wants
to store human tissues and cells for human application needs a licence.
Regarding the activities of procurement, testing of donor samples, pro-
cessing, import and export, and distribution of tissues and cells for human
application, either a licence or a third-party agreement with a licensed
establishment is required. Such a licence is currently provided by the HTA in
accordance with the Human Tissue (Quality and Safety for Human
Application) Regulations 2007 implementing the EU Directives on tissues
and cells.
2. The `hospital exemption'
As noted above, the ATMP Regulation provides a `hospital exemption';
ATMPs which are:
prepared on a non-routine basis according to specific quality standards, and
used within the same Member State in a hospital under the exclusive
responsibility of a medical practitioner, in order to comply with an individual
medical prescription for a custom-made product for an individual patient57
are not covered. Thus, manufacture under the hospital exemption must be
authorized by member states. In French law, ATMPs under the hospital
54 Article L1243-5 of the French Public Health Code.
55 Decree 2008-968, op. cit., n. 39.
56 Article R1243-1, op. cit., n. 39, and id.
57 ATMP Regulation, op. cit., n. 9, Preamble (6) and Article 28(2).
exemption were regulated as `preparations'. However, the new law adopted
to modify French law to comply with the ATMP Regulation provides that
only establishments or entities authorized by AFSSAPS, following an
opinion given by the Biomedecine Agency, and pharmaceutical establish-
ments, can prepare, preserve, distribute, and transfer ATMPs under the
hospital exemption, and in accordance with good practices to be defined by
the French agencies.58 A specific Decree will be adopted to define the
categories of establishments and modalities which can be authorized. In the
United Kingdom, the MHRA has provided guidance on what constitutes
non-routine preparation of a product.59 Two main questions are asked: first,
is it the same product, repeatedly under consideration? Second, what are the
scale and frequency of the preparation of the product? The MHRA has also
developed guidance on the United Kingdom's arrangements under the
hospital exemption scheme.60 This sets up specific standards, including on
good manufacturing practice and quality, pharmaco-vigilance, traceability,
sanctions and penalties, and requirements outside the Regulation such as
labelling, package leaflet requirements, and advertising. Such guidance does
not provide new legislative requirements under the hospital exemption,
stipulating that NHS trusts may deal with clinical ethical issues and the
GTAC could provide ethical advice.
Again, in both France and the United Kingdom, we can see the way in
which the attempt to regulate therapies not intended for commercial
marketing grapples with the `boundary work' of adapting existing regimes to
new laws, and the potential for uncertainty in applying classifications that
make commercially consequential sectoral (hospital, company) distinctions
between the actors in the regenerative therapy field.
3. Others categories in national laws
Separate from grafting and transplant and hospital exemption provisions,
France and the United Kingdom have a range of further provisions designed to
cover particular types of product or methods of preparation or production.
Space prohibits a full discussion of these, but we note the following key
points. First, in French law, gene therapy and xenogeneic cell and tissue
engineering preparations are considered as medicinal products although they
are not manufactured at an industrial scale. Establishments and processes have
to be authorized by AFSSAPS. Preparations from human tissue engineering
and human cell therapy fall under the regulations governing human cells and
tissues rather than medicinal products, a fine distinction reflecting the
particular history and basis of French law. Second, in British law, two other
58 See, notably, articles L4211-9, L5124-1, L5121-5 of the French Public Health Code.
59 MHRA, Annex B, Guidance on `non-routine'.
60 MHRA, ATMPs Guidance.
regimes can be applied to medicinal products based on genes, cells or tissues,
the pre-existing United Kingdom `Specials' exemption, or the Medicines Act
exemptions. These exemptions are complex and are under development at the
time of writing; at first sight, they appear difficult to distinguish from the
ATMP hospital exemption. The `specials' scheme provides that to `fulfil
special needs' the provisions of the medicines Directive need not be met to
respond to `a bona fide unsolicited order . . . for use by an individual patient'.
For such products only a manufacturer's licence is required. Further, although
in principle a product licence is required to procure, sell, supply or export a
medicinal product, along with a manufacturer's licence,61 exemptions are
provided for doctors and pharmacists by the Medicines Act 1968. Such
exemptions would apply to ATMPs as to other medicinal products.
Thus it appears that the regulatory work of providing for exemptions for
the production and use of regenerative therapy products in the EU regime is
being addressed strongly but differently in the United Kingdom and France
as they wrestle with existing regimes. The different ethically-motivated
emphasis between the two states reappears here, with France again relying
more on a standpoint on non-commodification (shown by the refusal to
qualify human cell or tissues based preparations as `products') compared to
the United Kingdom's greater concern with product licensing issues.
DISCUSSION
Processes of classification of medical products can be seen as part of society's
regulatory ordering of innovating technological sectors or zones.62 They
demonstrate change of constitutional significance in the relations between
living entities, technologies, and states.63 Society's regulatory classifications
of technology, as in other arenas, have important consequences for how risks
and benefits are perceived,64 constructed, and managed; what regimes of
evidence are brought into play; what private or public resources are deployed;
and what characteristics shape publics' approval or concerns about the uses of
the technology. The structuring work of classification is particularly striking
in the socio-medical and industrial worlds of medicine and healthcare.65
61 Section 7(2) of the Medicines Act 1968.
62 A. Faulkner, `Regulatory policy as innovation: constructing rules of engagement of a
technological zone for tissue engineering in the European Union' (2009) 38 Research
Policy 637±46.
63 S. Jasanoff, Designs on Nature: Science and Democracy in Europe and the United
States (2005).
64 For more detail, see M.L. Flear, `The EU's biopolitical governance of advanced
therapy medicinal products' (2009) 16 Maastricht J. of European and Comparative
Law 113±37.
65 G.C. Bowker and S.L. Star, Sorting Things Out: Classification and its Consequences
(2000).
Classifying and formalizing practices shape new kinds of attachments that
enrol persons in the performance of public practices such as medicine.66 One
of the main avowed aims of the law building that we have described here is to
achieve `legal clarity' for human tissues and cells for therapeutic use and for
regenerative technologies, and there is evidence of `commensuration'
processes67 in the regulatory work of aligning different types of medical
product with each other in the legislation discussed. Yet, in contrast, the high
degree of complexity in distinctions between different materials, production
processes, and institutional participants of regenerative medicine remains
evident from our descriptions of the key legal provisions in the EU and two
member states. The hybrid, transgressive characteristics of many investiga-
tional therapies and potential products is associated with a plethora of new
legal regulations and exemptions from them. Classifications can usefully be
seen as maps to the world of medical technologies. Indeed, in the United
Kingdom at least, the production of `roadmaps' by regulatory authorities is a
distinctive feature of their communication with the world of regenerative
medicine producers and researchers. Classifications emerge closely
associated with the development of experimental scientific and clinical
apparatuses as well as the production of scientific facts and institutional
organization. One metaphor for this is of elements being `mangled' together,
adapted to the extreme diversity of biomedical contingencies.68
How do we explain the detailed progress of classification and sub-
classification of different materials and production and preparation processes
constructing the `material world' of regenerative medicine? Is it merely a
question of the law progressively being evolved in attempts to respond to
unstable, complex biologies and technologies, as we asked in our intro-
duction? There are several answers to this question. First, from a legal point
of view, given the peculiar federal nature of the EU polity, a main motive of
classification comes from the principle of sharing competence between the
EU and its member states. The EU can only regulate where it has com-
petency, in this case, in cross-border movement of products (considered as
goods in EU law and therefore submitted to the principle of free movement
of goods) and where action at the EU level has added value in accordance
with the subsidiarity principle applying in the field of public health. Member
states may legislate individually on matters of national concern, such as, in
the case considered here, products derived from human embryonic stem
cells. This `top-down' argument should be supplemented by a `bottom-up'
approach, that is, local forms of regulatory adjustments involving stake-
holders at a national level. From a sociological point of view, one can
66 N. Marrres, `The Issues Deserve More Credit: Pragmatist contributions to the study of
public involvement in controversy' (2007) 37 Social Studies of Sci. 759±80.
67 W.N. Espeland and M.L. Stevens `Commensuration as a social process' (1998) 24
Ann. Rev. of Sociology 313±43.
68 A. Pickering, The Mangle of Practice: Time, Agency and Science (1995).
suggest that the `boundary work'69 of national implementation of EU laws
amounts to a form of partial `nationalization' of biomedical therapy and
biomedical `industry' ± a phenomenon that has been called `techno-
nationalism'.70 This may be so, but from a legal perspective, the preferred
interpretation would be that such boundary work is a national retention of
competency by member states, which can of course result in varying priority
being given to biomedicine. This boundary work of national implementation
of EU law can also be seen as a bottom-up process that materializes in
specific local spaces, which can be conceptualized as `technological
zones',71 characterized by the development of common standards and
assessments of objects and practices, neither clearly bounded nor necessarily
corresponding to the borders of nation-states.
Secondly, the agreed high level of risks for these biological products gives
rise to a high degree of stringency which requires regulatory attention to
procedures and products at a very high level of technical detailing. However,
the `stringency' that is being constructed here is ambiguous. On the one
hand, we see a high degree of elaboration of EU legal frameworks and
national provisions, providing for exceptions and adapting existing laws and
principles. But on the other hand, it is notable that the ATMP product law in
particular is open-ended on many matters concerning the technical assess-
ment of yet-to-emerge products, justified on the grounds that these cannot be
foreseen. Thus, issues of, for example, clinical data requirements for ATMPs
are left outside society's (parliamentary) review process for `comitology',
that is, to the technical committees of the European Medicines Agency and
its consultative processes.72
Thirdly, and particularly for France as this discussion shows, the human
materials character of these products highlights a distinctive classificatory
organizing principle which has complex ramifications and is based on the
strong attachment of French bioethics to respect for the autonomy and
integrity of the human body and its elements, resting on upholding the
ethical distinction between `the thing and the person'. This derives from
deep cultural and bioethical traditions, as well as being influenced by the
well-known blood contamination scandals which reached the highest
echelons of French government. Respect for the human body is expressed
differently in the United Kingdom's implementation of the recent EU laws,
69 T.F. Gieryn, `Boundary-work and the demarcation of science from non-science:
strains and interests in professional ideologies of scientists' (1983) 48 Am.
Sociological Rev. 781±95.
70 D. Edgerton, `The Contradictions of Techno-Nationalism and Techno-Globalism: A
Historical Perspective' (2007) 1 New Global Studies, at <http://www.bepress.com/
ngs/vol1/iss1/art1>.
71 A. Barry, `Technological Zones' (2006) 9 European J. of Social Theory 239±53;
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notably in the detailed exposition of the principle of informed consent in the
Human Tissue Act, whose ramifications are materialized more in social
procedures than in substantive person/property boundaries. Thus the two
systems are markedly different in approach, though it remains arguable as to
whether one is more or less `stringent' compared to the other.
The legal developments described here position the EU and individual
member states in the global world of regenerative medicine in which stake-
holders compete and collaborate.73 In the still-evolving legal framework, we
can see a mixture of measures designed to give commercial producers
improved access to the European marketplace while protecting indivi-
dualized biotherapies created in hospitals, and constructing stringent safety
and risk management regulations for both. Having noted differences in the
principles shaping the regulatory approaches of France and the United
Kingdom, it is of interest to ask if there are differences between the two
countries in the implications of the complex regulatory frameworks for
biotherapy producers and users or patients in the respective healthcare
systems. On the basis of this discussion, the implications appear similar in
France and the United Kingdom. Indeed, the regulations across the
differentiated categories of therapy are, in regulatory terms, deemed overall
to enhance competitiveness for companies and foster innovation, at the same
time providing, whether at EU or national level, very stringent requirements
regarding the high level of safety risk. For users and patients, there are
similar implications in the EU, and in France and the United Kingdom
individually, for patients to access safe medicinal products.74 Although clear
differences might emerge in the means and manner of reimbursement of
products, that topic is beyond the scope of the present article.
What can we conclude about comparing the configuration of the different
sets of regulatory institutions in each society, and how they `match', or not,
their corresponding, mobile regulatory objects and processes? These issues
have been discussed in relation to other biomedical technologies.75 As noted,
in France there is one primary national regulating agency for such products
(either medical materials or health products including medicinal products)
used for therapy, whereas in the United Kingdom three main national
agencies are relevant. It could be argued that the French set-up matches the
structure of the combined tissue and cells and advanced therapy framework
more closely than the United Kingdom's, because the Regulation does not
distinguish between different types of starting material, and this is also the
case with the French national agency, although it does contain different
73 S. Saurugger, TheÂories et concepts de l'inteÂgration europeÂenne (2009).
74 A. Mahalatchimy, `Access to advanced therapy medicinal products in the European
Union: where do we stand?' (2011) 18 European J. of Health Law 305±17.
75 N. Brown et al., `Regulating Hybrids: `` Making a Mess'' and `` Cleaning Up'' in
Tissue Engineering and Transpecies Transplantation' (2006) 4 Social Theory &
Health 1±24.
pathways and product categories. Conversely, the differentiated agencies in
the United Kingdom could also be seen as corresponding better to the two
sets of complementary EU regulations (for tissues and cells, and for
medicinal products) compared to the French agency. At the beginning of this
article, we posed the question of whether regulatory institutional structures
might `naturally' reflect unstable biological and technical categorizations, or
whether institutional structures were relatively `free-floating'. Our analysis
here, showing the wide national variation in structures implementing the
same EU-level laws designed and adapted to cover the same field, supports
the latter interpretation: regulatory institutional structures here have a high
degree of flexibility in relation to the `underlying' processes of material
innovation, though they strain against existing, inherited legislations. Indeed,
it would be more accurate to understand this not as `implementation' but
rather as a process of adaptation of EU laws, in which influence flows from
EU to national jurisdictions and vice versa, and, in sociological terms, one of
co-production between regulatory institutions and regulated `objects'.
`Local' expectations, fears, and promises surrounding regenerative
medicine's objects undoubtedly shape the institutional regulation of material
innovation, possibly to a greater degree than the scientific data that accom-
pany those objects.76 Governance activity has a constructive and shaping
action as well as standardizing some material practices. The dynamics of the
emerging medical world thus perform a complex web of codified legal
narratives.77
This review necessarily leaves some loose ends. Although a legal
framework has been created, some scientific and technological innovations
escape its categories. At the same time, some aspects of the regulation at EU
level are deliberately left loose, open to new technical developments. The
two countries discussed here attempt to reconcile new rules with pre-
existing, institutionalized pharmaceutical and human tissue related principles
± the `inherited regulatory environment'.78 Perhaps most notable in terms of
the materialization of law, in conclusion, is that alongside the elaborate
construction of a new regulatory framework at EU level and its adaptation in
national regimes, we also see that each new regenerative medicine product
will have to receive a unique scientific expert assessment before being made
available as a product in the healthcare system. It may be that the operation
of discretion by committees of selected specialists considering innovations
76 N. Brown, `Shifting Tenses ± From Regimes of Truth to Regimes of Hope?' (2007)
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Working Paper No.1, at <http:/ /www.jnu.ac.in/Academics/Schools/
SchoolOfSocialSciences/CSSP/CSSP-EWPS-1.pdf>.
78 Compare E. Stokes, `Nanotechnology and the Products of Inherited Regulation' in
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on a case-by-case basis will be the over-riding feature for deciding the
regulatory route that new products and their developers will have to take.
Experts' legitimacy here takes the form of institutional legitimacy via their
formal affiliation to the European Medicines Agency as a mandated Euro-
pean Agency, and the technical legitimacy afforded by specific recognized
skills. Thus, we conclude by pointing to the fact that, in spite of the
regulatory reach of a complex and highly detailed new legal framework, a
tailored case-by-case approach to deploying technical expertise nevertheless
is required in regulating the fast-moving, innovative arena of regenerative
medicine.
